surmount 4 tirzepatide Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity

Tirzepatide Scores Win in Second Obesity Trial, SURMOUNT-2

22.20

★★★★☆4.8 (126)

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency

24.31

★★★★★4.9 (98)

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4qaMLfO

21.25

★★★★★5.0 (157)

What's been your experience as a patient or a clinician prescribing these? Across all the data combined, patients stopping semaglutide or tirzepatide regain an average of 9.69 kg (around 20 pounds) -of

26.64

★★★★★4.7 (84)

Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial

24.19

★★★★★4.9 (203)

SURMOUNT-4 Trial results: the impact of tirzepatide on maintenance of weight reduction and benefits of continued therapy

27.85

★★★★★5.0 (176)

Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial | Diabetes Therapy

24.81

★★★★★4.8 (132)